The purpose of the study is to measure the levels of caffeine in saliva samples from premature babies receiving this treatment and to see how these levels relate to how long the babies need breathing support with machines. During the study, saliva samples will be collected from the babies at different times to measure caffeine levels. Researchers will observe how well the babies respond to the treatment by tracking how long they need help with breathing machines, how often they have episodes where they stop breathing, and when they can safely stop taking the caffeine medication. The study will also look at whether caffeine levels affect pain scores and vital signs like heart rate and blood pressure.

The study will monitor various health outcomes in these premature babies, including complications that can occur in very early babies such as lung problems, eye problems, heart problems, and brain-related issues. Researchers will also track any side effects that may be related to the caffeine treatment, such as fast heart rate, seizures, irritability, feeding problems, or changes in urine output. Additionally, the study will examine how the babies’ bodies process caffeine by measuring both caffeine and a substance called paraxanthine in their saliva, which helps understand how quickly each baby breaks down the medication.

The purpose of the study is to see if giving an extra dose of caffeine citrate before removing the breathing tube can improve the chances of successful extubation. The study will monitor the need for reintubation, which means putting the breathing tube back in if the baby struggles to breathe on their own. It will also look at other factors like the frequency of breathing pauses (apneas), side effects such as increased heart rate or blood pressure, and any digestive issues. Additionally, the study will observe the development of conditions like necrotizing enterocolitis, a serious intestinal disease, and the progression of brain-related issues such as intraventricular hemorrhage or periventricular leukomalacia.

The trial will follow the participants over a period to assess their neurodevelopmental outcome, which refers to how well their brain develops and functions over time. The study aims to provide valuable insights into whether this additional caffeine citrate dose can help improve breathing outcomes and overall health in these vulnerable infants.

The purpose of the study is to see if the automatic system can improve outcomes for these infants, such as reducing the risk of complications like retinopathy of prematurity (a serious eye condition), chronic lung disease, and necrotizing enterocolitis (a severe intestinal disease). The study will also look at the overall survival and development of the infants up to 24 months after their expected due date. The trial will involve monitoring the infants closely to see if the automatic system provides better results than the manual method.

Throughout the study, infants will receive oxygen through standard infant ventilators, which are machines that help them breathe. The trial will last until the infants are discharged from the hospital, and their development will be assessed at 24 months. This research is important to potentially improve the care and outcomes for extremely preterm infants by ensuring they receive the right amount of oxygen in a safe and effective way.

During the study, preterm newborns will receive either doxapram or a placebo. The treatment will be administered over a period of time, and the infants will be monitored closely by healthcare professionals. The study aims to observe the effects of the treatment on the infants’ health and development up to the age of 18 to 24 months.

The trial is designed to provide valuable information on whether doxapram can help improve outcomes for preterm infants with apnea of prematurity. By comparing the results between those receiving doxapram and those receiving a placebo, researchers hope to gain insights into the potential benefits and safety of this treatment for vulnerable newborns.